RXRX Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals has a net margin of -1366.49% compared to Recursion Pharmaceuticals's net margin of -111.65%. Recursion Pharmaceuticals's return on equity of -82.61% beat Ionis Pharmaceuticals's return on equity of -100.15%.

Recursion Pharmaceuticals has a consensus price target of $7.14, signalling upside risk potential of 29.4%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $58.30 which suggests that it could grow by 38.26%. Given that Ionis Pharmaceuticals has higher upside potential than Recursion Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Recursion Pharmaceuticals.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.230, suggesting its less volatile than the S&P 500 by 77.021%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $14.8M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $131.6M. Recursion Pharmaceuticals's net income of -$202.5M is lower than Ionis Pharmaceuticals's net income of -$146.9M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 29.16x versus 8.98x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -1366.49% compared to Recursion Pharmaceuticals's net margin of 21.63%. Recursion Pharmaceuticals's return on equity of -82.61% beat Pfizer's return on equity of 8.72%.

Recursion Pharmaceuticals has a consensus price target of $7.14, signalling upside risk potential of 29.4%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.92%. Given that Recursion Pharmaceuticals has higher upside potential than Pfizer, analysts believe Recursion Pharmaceuticals is more attractive than Pfizer.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.92% to investors and pays a quarterly dividend of $0.43 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $14.8M, which are smaller than Pfizer quarterly revenues of $13.7B. Recursion Pharmaceuticals's net income of -$202.5M is lower than Pfizer's net income of $3B. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 29.16x versus 2.24x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Rallybio has a net margin of -1366.49% compared to Recursion Pharmaceuticals's net margin of -4452.36%. Recursion Pharmaceuticals's return on equity of -82.61% beat Rallybio's return on equity of -67.73%.

Recursion Pharmaceuticals has a consensus price target of $7.14, signalling upside risk potential of 29.4%. On the other hand Rallybio has an analysts' consensus of $1.00 which suggests that it could grow by 119.93%. Given that Rallybio has higher upside potential than Recursion Pharmaceuticals, analysts believe Rallybio is more attractive than Recursion Pharmaceuticals.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rallybio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rallybio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. Rallybio pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $14.8M, which are larger than Rallybio quarterly revenues of $212K. Recursion Pharmaceuticals's net income of -$202.5M is lower than Rallybio's net income of -$9.4M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while Rallybio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 29.16x versus 23.88x for Rallybio. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -1366.49% compared to Recursion Pharmaceuticals's net margin of 4.19%. Recursion Pharmaceuticals's return on equity of -82.61% beat TG Therapeutics's return on equity of 19.78%.

Recursion Pharmaceuticals has a consensus price target of $7.14, signalling upside risk potential of 29.4%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 3.34%. Given that Recursion Pharmaceuticals has higher upside potential than TG Therapeutics, analysts believe Recursion Pharmaceuticals is more attractive than TG Therapeutics.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $14.8M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Recursion Pharmaceuticals's net income of -$202.5M is lower than TG Therapeutics's net income of $5.1M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 163.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 29.16x versus 16.31x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.